The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
May 14th 2024
Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Venetoclax/Rituximab Maintains PFS Advantage With uMRD in Relapsed/Refractory CLL
October 13th 2020A fixed-duration of venetoclax plus rituximab led to sustained and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia who achieved undetectable minimal residual disease.
The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL
September 28th 2020Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.
Acalabrutinib Shows Sustained Superiority Over Standard-of-Care Regimens in Relapsed/Refractory CLL
September 11th 2020Acalabrutinib continued to show prolonged progression-free survival with a favorable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk features.
Ofatumumab to Be Available Through a Patient Access Program for CLL
September 10th 2020Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.